Lars van der Veken

Researcher/Postdoc

Strategic program(s):

Contact

lveken@umcutrecht.nl

Pure profile

Recent publications

All publications

Exploring germline variants in genes associated with inborn errors of immunity and inherited bone marrow failure syndromes in pediatric hematological malignancies Jette J. Bakhuizen, Freerk van Dijk, Sebastian B.B. Bon, Lars T. van der Veken, Manon M.H. Huibers, Joris M. van Montfrans, Marieke De Bruyne, Barbara De Moerloose, Filomeen Haerynck, Jan L.C. Loeffen, Tim Lammens, Roland P. Kuiper, Marjolijn C.J. Jongmans, Delfien J.A. Bogaert
European Journal of Cancer, 2025, vol. 226

Comprehensive reanalysis for CNVs in ES data from unsolved rare disease cases results in new diagnoses German Demidov, Burcu Yaldiz, José Garcia-Pelaez, Elke de Boer, Nika Schuermans, Liedewei Van de Vondel, Ida Paramonov, Lennart F. Johansson, Francesco Musacchia, Elisa Benetti, Gemma Bullich, Karolis Sablauskas, Sergi Beltran, Christian Gilissen, Alexander Hoischen, Stephan Ossowski, Richarda de Voer, Katja Lohmann, Carla Oliveira, Ana Topf, Lisenka E.L.M. Vissers, Kristina Zguro, Federico Zara, Ioannis Zaganas, Vicente A. Yépez, Brunhilde Wirth, David Webb, Hannah Verdin, Erika Van Nieuwenhove, Joris van Montfrans, Roxane van Heurck, Lars van der Veken, Laura Valle, Paolo Uva, Bjarne Udd, Aurelien Trimouille, Rachel Thompson, Marco Tartaglia, Yves Sznajer, Pasquale Striano, Verena Steinke-Lange, Martha Spilioti, Paolo Scudieri, Evelin Schröck, Katherine Schon, Marcello Scala, Helen Leavis, Manon Huibers, Marielle van Gijn, Geert de Vries, , Steven Laurie
npj Genomic Medicine, 2024, vol. 9

Recombinant Interleukin-1 Receptor antagonist is an effective first-line treatment strategy in new-onset systemic Juvenile Idiopathic Arthritis, irrespective of HLA-DRB1 background and IL1RN variants Remco G A Erkens, Jorg J A Calis, Anouk Verwoerd, Sytze De Roock, Nienke M Ter Haar, Gerda Den Engelsman, Lars T Van der Veken, Robert F Ernst, Hanneke W M Van Deutekom, Alex Pickering, Rianne C Scholman, Marc H A Jansen, Joost F Swart, Rashmi Sinha, Johannes Roth, Grant S Schulert, Alexei A Grom, Jorg Van Loosdregt, Sebastiaan J Vastert
Arthritis & Rheumatology, 2023, vol. 76, p.119-129

Clinical Symptoms, Laboratory Parameters and Long-Term Follow-up in a National DADA2 Cohort Marie Valérie E Andriessen, G Elizabeth Legger, Robbert G M Bredius, Marielle E van Gijn, A Elisabeth Hak, Petra C E Hissink Muller, Sylvia Kamphuis, Femke C C Klouwer, Taco W Kuijpers, Helen L Leavis, Stefan Nierkens, Abraham Rutgers, Lars T van der Veken, Gijs T J van Well, Catharina M Mulders-Manders, Joris M van Montfrans
Journal of Clinical Immunology, 2023, vol. 43, p.1581-1596

A cis-regulatory element regulates ERAP2 expression through autoimmune disease risk SNPs Wouter J Venema, Sanne Hiddingh, Jorg van Loosdregt, John Bowes, Brunilda Balliu, Joke H de Boer, Jeannette Ossewaarde-van Norel, Susan D Thompson, Carl D Langefeld, Aafke de Ligt, Lars T van der Veken, Peter H L Krijger, Wouter de Laat, Jonas J W Kuiper
Cell genomics, 2023, vol. 4

Prolonged Disease Course of COVID-19 in a Patient with CTLA-4 Haploinsufficiency T W Hoffman, H L Leavis, B M Smits, L T van der Veken, D A van Kessel
Case reports in immunology, 2023, vol. 2023